BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//www.barthsyndrome.org//NONSGML kigkonsult.se iCalcreator 2.30.10/
 /
CALSCALE:GREGORIAN
METHOD:PUBLISH
UID:57f0b361-bac8-416a-a633-756d9513e4bf
X-WR-CALDESC:\nDuring this presentation Dr. Brian Boyarsky will discuss his
  team’s ongoing and recently published efforts to assess how well an immun
 e response is generated\, or the immunogenicity\, of mRNA-based COVID vacc
 ines (Pfizer/BioNTech and Moderna) in solid organ transplant recipients.\n
 \nThis effort is of immense interest and value for the Barth and transplan
 t communities as individuals with compromised immune systems were excluded
  in the mRNA vaccine trials. Furthermore\, given the daily regimen of immu
 ne-suppressing drugs taken by our community of transplanted individuals\, 
 understanding the interplay of mRNA COVID vaccines and transplant status h
 as long-term and real-time impact as we navigate our way through the pande
 mic. Join us to hear Dr. Boyarsky discuss the scope\, findings\, and next 
 steps of the National Vaccine Research Study for Transplant recipients bei
 ng conducted by the Epidemiology Research Group in Organ Transplantation.
 \n\nDr. Boyarsky is a surgery resident at the Johns Hopkins University Sch
 ool of Medicine\, Department of Surgery. He graduated with his medical deg
 ree at Rutgers Robert Wood Johnson Medical School and recently earned his 
 PhD from the Johns Hopkins Bloomberg School of Public Health under the men
 torship of Dorry L. Segev\, MD\, PhD.
X-WR-RELCALID:b729b1315c9695dac92ec22abe6f3db3
X-WR-TIMEZONE:America/New_York
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:STANDARD
TZNAME:EST
DTSTART:20201101T020000
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
RDATE:20211107T020000
RDATE:20221106T020000
END:STANDARD
BEGIN:DAYLIGHT
TZNAME:EDT
DTSTART:20210314T020000
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
RDATE:20220313T020000
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:2637bf40-8c67-45f8-b7eb-b165c6ba50b1
DTSTAMP:20260428T031820Z
DESCRIPTION:\nDuring this presentation Dr. Brian Boyarsky will discuss his 
 team’s ongoing and recently published efforts to assess how well an immune
  response is generated\, or the immunogenicity\, of mRNA-based COVID vacci
 nes (Pfizer/BioNTech and Moderna) in solid organ transplant recipients.\n
 \nThis effort is of immense interest and value for the Barth and transplan
 t communities as individuals with compromised immune systems were excluded
  in the mRNA vaccine trials. Furthermore\, given the daily regimen of immu
 ne-suppressing drugs taken by our community of transplanted individuals\, 
 understanding the interplay of mRNA COVID vaccines and transplant status h
 as long-term and real-time impact as we navigate our way through the pande
 mic. Join us to hear Dr. Boyarsky discuss the scope\, findings\, and next 
 steps of the National Vaccine Research Study for Transplant recipients bei
 ng conducted by the Epidemiology Research Group in Organ Transplantation.
 \n\nDr. Boyarsky is a surgery resident at the Johns Hopkins University Sch
 ool of Medicine\, Department of Surgery. He graduated with his medical deg
 ree at Rutgers Robert Wood Johnson Medical School and recently earned his 
 PhD from the Johns Hopkins Bloomberg School of Public Health under the men
 torship of Dorry L. Segev\, MD\, PhD.
DTSTART;TZID=America/New_York:20210527T120000
DTEND;TZID=America/New_York:20210527T130000
LOCATION:https://barthsyndrome.zoom.us/webinar/register/WN_VWkmb-P3Qu6175kA
 uOceYA
SUMMARY:Webinar: COVID-19 Vaccine Antibody Response in Transplant Patients
END:VEVENT
END:VCALENDAR